Using Quality-Adjusted Progression-Free Survival as an Outcome Measure to Assess the Benefits of Cancer Drugs in Randomized-Controlled Trials: Case of the BOLERO-2 Trial

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-014-3047-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P1.15-29 Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Using Routinely Recorded Data in the UK to Assess Outcomes in a Randomised Controlled Trial: The Trials of Access

Trials
MedicinePharmacology
2017English

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs

JAMA network open
Medicine
2019English

Negative Phase 3 Randomized Controlled Trials: Why Cancer Drugs Fail the Last Barrier?

International Journal of Cancer
Cancer ResearchOncology
2018English

Description of the Protocols for Randomized Controlled Trials on Cancer Drugs Conducted in Spain (1999–2003)

PLoS ONE
Multidisciplinary
2013English

Evolving Options for the Treatment of Metastatic Breast Cancer: Progression-Free Survival as an Endpoint

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2011English

Use of Continuous Glucose Monitoring as an Outcome Measure in Clinical Trials

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2012English

TRIal to Slow the Progression of Diabetes (TRIPOD): Study Protocol for a Randomized Controlled Trial Using Wireless Technology and Incentives

Trials
MedicinePharmacology
2019English

Perspectives of Patients With Cancer on the Quality-Adjusted Life Year as a Measure of Value in Healthcare

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy